STIVARGA

STIVARGA® is a prescription anticancer medicine containing regorafenib, offered as a once-daily oral treatment for certain adults whose cancer has progressed after previous therapy. The patient website explains its use in three conditions: metastatic colorectal cancer (mCRC) that has spread and was previously treated with certain chemotherapy medicines; gastrointestinal stromal tumor (GIST) that cannot be removed by surgery or has spread, following prior treatment with certain medicines; and hepatocellular carcinoma (HCC), a type of liver cancer, after treatment with sorafenib. STIVARGA is a multikinase inhibitor and is described as a chemo-free oral option for previously treated mCRC.

The site provides information on taking the medicine, possible side effects and how to manage them, along with patient resources, videos, questions to discuss with a doctor, and financial support and access information, including a co-pay program for eligible patients. It also emphasizes important safety information: STIVARGA can cause severe, potentially fatal liver problems and other serious side effects. Patients should review the Prescribing Information and consult their healthcare provider